Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study
Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant treatment response; yet their clinical relevance is not fully established. Therefore, we here investigate if (1) cognitive performance improves ov...
Gespeichert in:
| Veröffentlicht in: | Translational psychiatry Jg. 12; H. 1; S. 468 - 8 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
Nature Publishing Group UK
08.11.2022
Nature Publishing Group |
| Schlagworte: | |
| ISSN: | 2158-3188, 2158-3188 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant treatment response; yet their clinical relevance is not fully established. Therefore, we here investigate if (1) cognitive performance improves over the course of antidepressant treatment and (2) cognitive performance at baseline is predictive of antidepressant treatment response. In the NeuroPharm study (clinical trial id: NCT02869035), 92 antidepressant-free patients with a moderate to severe depressive episode were assessed with a comprehensive cognitive test battery including both cold (emotion-independent) and hot (emotion-dependent) tasks. Patients were tested before and after 12 weeks of standard antidepressant treatment with escitalopram in flexible doses of 10–20 mg. Performance improved across most cognitive domains over the course of antidepressant treatment. Notably, these improvements were independent of improvement in mood symptoms, emphasizing that cognitive disturbances are a distinct symptom and therefore treatment target in MDD. Results did not suggest that performance on any single cognitive measure at baseline was associated with later clinical response to antidepressant treatment. However, a small cluster of patients (
N
= 28) with globally disturbed cognition at baseline exhibited poorer clinical response after 8 but not 12 weeks of antidepressant treatment, suggesting that severe cognitive disturbances may delay treatment response. Thus, while pretreatment cognitive performance on individual tests may not be useful as clinical markers of treatment response, profiles capturing performance across different cognitive domains may be useful for stratification of patients with MDD and could be helpful in future intervention trials. |
|---|---|
| AbstractList | Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant treatment response; yet their clinical relevance is not fully established. Therefore, we here investigate if (1) cognitive performance improves over the course of antidepressant treatment and (2) cognitive performance at baseline is predictive of antidepressant treatment response. In the NeuroPharm study (clinical trial id: NCT02869035), 92 antidepressant-free patients with a moderate to severe depressive episode were assessed with a comprehensive cognitive test battery including both cold (emotion-independent) and hot (emotion-dependent) tasks. Patients were tested before and after 12 weeks of standard antidepressant treatment with escitalopram in flexible doses of 10–20 mg. Performance improved across most cognitive domains over the course of antidepressant treatment. Notably, these improvements were independent of improvement in mood symptoms, emphasizing that cognitive disturbances are a distinct symptom and therefore treatment target in MDD. Results did not suggest that performance on any single cognitive measure at baseline was associated with later clinical response to antidepressant treatment. However, a small cluster of patients (N = 28) with globally disturbed cognition at baseline exhibited poorer clinical response after 8 but not 12 weeks of antidepressant treatment, suggesting that severe cognitive disturbances may delay treatment response. Thus, while pretreatment cognitive performance on individual tests may not be useful as clinical markers of treatment response, profiles capturing performance across different cognitive domains may be useful for stratification of patients with MDD and could be helpful in future intervention trials. Abstract Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant treatment response; yet their clinical relevance is not fully established. Therefore, we here investigate if (1) cognitive performance improves over the course of antidepressant treatment and (2) cognitive performance at baseline is predictive of antidepressant treatment response. In the NeuroPharm study (clinical trial id: NCT02869035), 92 antidepressant-free patients with a moderate to severe depressive episode were assessed with a comprehensive cognitive test battery including both cold (emotion-independent) and hot (emotion-dependent) tasks. Patients were tested before and after 12 weeks of standard antidepressant treatment with escitalopram in flexible doses of 10–20 mg. Performance improved across most cognitive domains over the course of antidepressant treatment. Notably, these improvements were independent of improvement in mood symptoms, emphasizing that cognitive disturbances are a distinct symptom and therefore treatment target in MDD. Results did not suggest that performance on any single cognitive measure at baseline was associated with later clinical response to antidepressant treatment. However, a small cluster of patients (N = 28) with globally disturbed cognition at baseline exhibited poorer clinical response after 8 but not 12 weeks of antidepressant treatment, suggesting that severe cognitive disturbances may delay treatment response. Thus, while pretreatment cognitive performance on individual tests may not be useful as clinical markers of treatment response, profiles capturing performance across different cognitive domains may be useful for stratification of patients with MDD and could be helpful in future intervention trials. Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant treatment response; yet their clinical relevance is not fully established. Therefore, we here investigate if (1) cognitive performance improves over the course of antidepressant treatment and (2) cognitive performance at baseline is predictive of antidepressant treatment response. In the NeuroPharm study (clinical trial id: NCT02869035), 92 antidepressant-free patients with a moderate to severe depressive episode were assessed with a comprehensive cognitive test battery including both cold (emotion-independent) and hot (emotion-dependent) tasks. Patients were tested before and after 12 weeks of standard antidepressant treatment with escitalopram in flexible doses of 10-20 mg. Performance improved across most cognitive domains over the course of antidepressant treatment. Notably, these improvements were independent of improvement in mood symptoms, emphasizing that cognitive disturbances are a distinct symptom and therefore treatment target in MDD. Results did not suggest that performance on any single cognitive measure at baseline was associated with later clinical response to antidepressant treatment. However, a small cluster of patients (N = 28) with globally disturbed cognition at baseline exhibited poorer clinical response after 8 but not 12 weeks of antidepressant treatment, suggesting that severe cognitive disturbances may delay treatment response. Thus, while pretreatment cognitive performance on individual tests may not be useful as clinical markers of treatment response, profiles capturing performance across different cognitive domains may be useful for stratification of patients with MDD and could be helpful in future intervention trials.Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant treatment response; yet their clinical relevance is not fully established. Therefore, we here investigate if (1) cognitive performance improves over the course of antidepressant treatment and (2) cognitive performance at baseline is predictive of antidepressant treatment response. In the NeuroPharm study (clinical trial id: NCT02869035), 92 antidepressant-free patients with a moderate to severe depressive episode were assessed with a comprehensive cognitive test battery including both cold (emotion-independent) and hot (emotion-dependent) tasks. Patients were tested before and after 12 weeks of standard antidepressant treatment with escitalopram in flexible doses of 10-20 mg. Performance improved across most cognitive domains over the course of antidepressant treatment. Notably, these improvements were independent of improvement in mood symptoms, emphasizing that cognitive disturbances are a distinct symptom and therefore treatment target in MDD. Results did not suggest that performance on any single cognitive measure at baseline was associated with later clinical response to antidepressant treatment. However, a small cluster of patients (N = 28) with globally disturbed cognition at baseline exhibited poorer clinical response after 8 but not 12 weeks of antidepressant treatment, suggesting that severe cognitive disturbances may delay treatment response. Thus, while pretreatment cognitive performance on individual tests may not be useful as clinical markers of treatment response, profiles capturing performance across different cognitive domains may be useful for stratification of patients with MDD and could be helpful in future intervention trials. Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant treatment response; yet their clinical relevance is not fully established. Therefore, we here investigate if (1) cognitive performance improves over the course of antidepressant treatment and (2) cognitive performance at baseline is predictive of antidepressant treatment response. In the NeuroPharm study (clinical trial id: NCT02869035), 92 antidepressant-free patients with a moderate to severe depressive episode were assessed with a comprehensive cognitive test battery including both cold (emotion-independent) and hot (emotion-dependent) tasks. Patients were tested before and after 12 weeks of standard antidepressant treatment with escitalopram in flexible doses of 10–20 mg. Performance improved across most cognitive domains over the course of antidepressant treatment. Notably, these improvements were independent of improvement in mood symptoms, emphasizing that cognitive disturbances are a distinct symptom and therefore treatment target in MDD. Results did not suggest that performance on any single cognitive measure at baseline was associated with later clinical response to antidepressant treatment. However, a small cluster of patients ( N = 28) with globally disturbed cognition at baseline exhibited poorer clinical response after 8 but not 12 weeks of antidepressant treatment, suggesting that severe cognitive disturbances may delay treatment response. Thus, while pretreatment cognitive performance on individual tests may not be useful as clinical markers of treatment response, profiles capturing performance across different cognitive domains may be useful for stratification of patients with MDD and could be helpful in future intervention trials. |
| ArticleNumber | 468 |
| Author | Cheng Ip Dam, Vibeke Høyrup Köhler-Forsberg, Kristin Jørgensen, Martin Balslev Ozenne, Brice Stenbæk, Dea Siggaard Sahakian, Barbara Jacquelyn Knudsen, Gitte Moos Frokjaer, Vibe Gedsoe |
| Author_xml | – sequence: 1 givenname: Vibeke Høyrup orcidid: 0000-0001-5467-5159 surname: Dam fullname: Dam, Vibeke Høyrup email: Vibeke.dam@nru.dk organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 2 givenname: Dea Siggaard surname: Stenbæk fullname: Stenbæk, Dea Siggaard organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Psychology, University of Copenhagen – sequence: 3 givenname: Kristin surname: Köhler-Forsberg fullname: Köhler-Forsberg, Kristin organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 4 surname: Cheng Ip fullname: Cheng Ip organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Department of Clinical Pharmacology, Lundbeck Pharma A/S – sequence: 5 givenname: Brice surname: Ozenne fullname: Ozenne, Brice organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Department of Public Health, Section of Biostatistics, University of Copenhagen – sequence: 6 givenname: Barbara Jacquelyn orcidid: 0000-0001-7352-1745 surname: Sahakian fullname: Sahakian, Barbara Jacquelyn organization: Department of Psychiatry, University of Cambridge, Behavioral and Clinical Neuroscience Institute, University of Cambridge – sequence: 7 givenname: Gitte Moos orcidid: 0000-0003-1508-6866 surname: Knudsen fullname: Knudsen, Gitte Moos organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 8 givenname: Martin Balslev orcidid: 0000-0002-1321-8901 surname: Jørgensen fullname: Jørgensen, Martin Balslev organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Psychiatric Center Copenhagen – sequence: 9 givenname: Vibe Gedsoe surname: Frokjaer fullname: Frokjaer, Vibe Gedsoe organization: Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Department of Psychology, University of Copenhagen, Psychiatric Center Copenhagen |
| BookMark | eNp9UstuFDEQHKEg8iA_wMkSFy4T_JyxOSBFUYBIEXCAs-W1eyZezdiL7VkpH8E_482ugOQQS5Zb3VXVrXadNkchBmiaNwRfEMzk-8wJU7LFlO4uxy150ZxQImTLiJRH_8XHzXnOa1yP4JL05FVzzDrGe8nFSfP7emumxRQfRmTjGHzxW0DO57KklQkWMjIZlQSmzBAKKiaNUJAJDm0SOG9LTCgONVG8g5rKuYbI2OJjQD6g2awr4lA6aMfkIH1Al-grLCl-vzNpRrWhu3_dvBzMlOH88J41Pz9d_7j60t5--3xzdXnbWkH60lIOwjjSWUsHRYArusKKUjrglcGMKscH3FlJKLiBQA0JBjXYTlHbMWsxO2tu9roumrXeJD-bdK-j8fohEdOoTSreTqC7FemFFYJw4JwJIZUZeoEts7gfGKiq9XGvtVlWMzhbt5TM9Ej0cSX4Oz3GrVYdZ6zvqsC7g0CKvxbIRc8-W5gmEyAuWdOe8Y50GO96vX0CXcclhbqqHYrJTgolK4ruUTbFnBMMf4chWO_Mo_fm0dU4-sE8mlSSfEKyvpjdL9ah_fQ8le2pufYJI6R_Uz3D-gN1hNw0 |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0328886 crossref_primary_10_1093_ijnp_pyad041 crossref_primary_10_1016_j_biopsych_2024_08_009 crossref_primary_10_1016_j_pnpbp_2024_111095 crossref_primary_10_1016_j_bpsc_2023_03_014 crossref_primary_10_1016_j_jpsychires_2024_11_043 crossref_primary_10_1186_s13148_024_01678_y crossref_primary_10_1186_s12888_023_04618_x crossref_primary_10_1007_s11065_023_09629_9 crossref_primary_10_1038_s41380_023_02285_8 crossref_primary_10_1016_j_pscychresns_2025_111984 crossref_primary_10_3390_healthcare11070950 crossref_primary_10_1002_ibra_12167 crossref_primary_10_3758_s13415_023_01116_1 crossref_primary_10_1016_j_jpsychires_2024_01_026 |
| Cites_doi | 10.1177/0269881115581093 10.3389/fpsyg.2019.02660 10.2174/1871527313666141130205713 10.1017/S0033291716003123 10.1017/S0033291720000938 10.1038/475027a 10.1097/YCO.0000000000000378 10.1017/S0033291712002085 10.3389/fpsyt.2020.00641 10.1007/s11065-018-9369-5 10.1186/s12888-019-2410-2 10.1038/tp.2016.130 10.1016/j.bbr.2018.07.011 10.1038/npp.2011.183 10.1038/npp.2014.333 10.1016/S2215-0366(16)00012-2 10.1017/S0033291713002535 10.1017/S1461145714000546 10.1017/S0033291720004286 10.4088/JCP.13r08560 10.1007/s11033-019-05129-3 10.1002/da.22063 10.1098/rstb.2012.0407 10.1007/s00213-019-05448-0 10.1176/ajp.2006.163.11.1905 10.1016/S2215-0366(19)30291-3 10.1176/appi.ajp.163.1.28 10.3389/fpsyg.2020.00961 10.3389/fpsyt.2018.00382 10.1016/j.euroneuro.2018.11.1102 10.1016/j.jad.2014.10.047 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2022 – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1038/s41398-022-02240-1 |
| DatabaseName | Springer Nature OA/Free Journals CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2158-3188 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_6b175c5514e4435589af750c3c07f3e9 PMC9643376 10_1038_s41398_022_02240_1 |
| GrantInformation_xml | – fundername: Innovationsfonden (Innovation Fund Denmark) grantid: 4108-00004B funderid: https://doi.org/10.13039/100012774 – fundername: Augustinus Fonden (Augustinus Foundation) grantid: 16-0058 funderid: https://doi.org/10.13039/501100004954 – fundername: ; grantid: 16-0058 – fundername: ; grantid: 4108-00004B |
| GroupedDBID | --- 0R~ 3V. 53G 5VS 7X7 88E 8FI 8FJ AAJSJ AAKDD ABUWG ACGFO ACGFS ACMJI ACSMW ADBBV ADFRT AENEX AFKRA AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS BAWUL BCNDV BENPR BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EMOBN FYUFA GROUPED_DOAJ GX1 HMCUK HYE KQ8 LGEZI LOTEE M1P M~E NADUK NAO NXXTH OK1 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD CITATION PHGZM PHGZT PJZUB PPXIY 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c517t-24e5ad16cc2f91e492b09222f0ba0329d4f06c812edf1e06c10e9fc692c63cc03 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000880336000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2158-3188 |
| IngestDate | Fri Oct 03 12:45:54 EDT 2025 Tue Nov 04 02:09:02 EST 2025 Thu Sep 04 19:38:29 EDT 2025 Sat Nov 29 14:52:02 EST 2025 Sat Nov 29 02:05:49 EST 2025 Tue Nov 18 21:36:30 EST 2025 Fri Feb 21 02:39:04 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c517t-24e5ad16cc2f91e492b09222f0ba0329d4f06c812edf1e06c10e9fc692c63cc03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0003-1508-6866 0000-0001-7352-1745 0000-0001-5467-5159 0000-0002-1321-8901 |
| OpenAccessLink | https://www.proquest.com/docview/2733868598?pq-origsite=%requestingapplication% |
| PMID | 36347845 |
| PQID | 2733868598 |
| PQPubID | 2041978 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6b175c5514e4435589af750c3c07f3e9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9643376 proquest_miscellaneous_2734616009 proquest_journals_2733868598 crossref_primary_10_1038_s41398_022_02240_1 crossref_citationtrail_10_1038_s41398_022_02240_1 springer_journals_10_1038_s41398_022_02240_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-08 |
| PublicationDateYYYYMMDD | 2022-11-08 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Translational psychiatry |
| PublicationTitleAbbrev | Transl Psychiatry |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | RushAJTrivediMHWisniewskiSRNierenbergAAStewartJWWardenDAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D reportAm J Psychiatry200616319051710.1176/ajp.2006.163.11.190517074942 CleareAParianteCMYoungAHAndersonIMChristmasDCowenPJEvidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelinesJ Psychopharmacol2015294595251:CAS:528:DC%2BC2MXhtlWlu7%2FO10.1177/026988111558109325969470 Ang YS, Bruder GE, Keilp JG, Rutherford A, Alschuler DM, Pechtel P, et al. Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychol Med. 2020:1–9. https://doi.org/10.1017/S0033291720004286. Epub ahead of print. Pitsillou E, Bresnehan S, Kagarakis E, Wijoyo S, Liang J, Hung A, et al. The cellular and molecular basis of major depressive disorder: Towards a unified model for understanding clinical depression. Mol Biol Rep. 2019;47:753–70. ShilyanskyCWilliamsLMGyurakAHarrisAUsherwoodTEtkinAEffect of antidepressant treatment on cognitive impairments associated with depression: A randomised longitudinal studyLancet Psychiatry201634253510.1016/S2215-0366(16)00012-2269952984860142 RockPLRoiserJPRiedelWJBlackwellADCognitive impairment in depression: A systematic review and meta-analysisPsychol Med2014442029401:STN:280:DC%2BC2c7gslaquw%3D%3D10.1017/S003329171300253524168753 KnightMJBauneBTCognitive dysfunction in major depressive disorderCurr Opin Psychiatry201831263110.1097/YCO.000000000000037829076892 ParkCPanZBrietzkeESubramaniapillaiMRosenblatJDZuckermanHPredicting antidepressant response using early changes in cognition: A systematic reviewBehav Brain Res2018353154601:CAS:528:DC%2BC1cXhtl2jtbjM10.1016/j.bbr.2018.07.01130031025 DunlopBWParikhSVRothschildAJThaseMEDeBattistaCConwayCRComparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBMC Psychiatry2019191:CAS:528:DC%2BC1MXisFSjs7vE10.1186/s12888-019-2410-2318819566935147 CollinsPYPatelVJoestlSSMarchDInselTRDaarASGrand challenges in global mental healthNature.201147527301:CAS:528:DC%2BC3MXosFehurs%3D10.1038/475027a217346853173804 Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018;28:32–72. OstergaardSDBechPMiskowiakKWFewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D(6)) as outcome measureJ Affect Disord2016190842510.1016/j.jad.2014.10.04725487682 Hjordt LV, Ozenne B, Armand S, Dam VH, Jensen CG, Köhler-Forsberg K, et al. Psychometric properties of the verbal affective memory Test-26 and evaluation of affective biases in major depressive disorder. Front Psychol. 2020;11:961. Dam VH, Stenbæk DS, Köhler-Forsberg K, Ip C, Ozenne B, Sahakian BJ, et al. Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: A NeuroPharm study. Psychol Med. 2020;51:1–10. DamVHThystrupCKJensenPSBlandARMortensenELElliottRPsychometric properties and validation of the EMOTICOM test battery in a healthy Danish populationFront Psychol201910266010.3389/fpsyg.2019.02660318497726901831 TrivediMHRushAJWisniewskiSRNierenbergAAWardenDRitzLEvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry2006163284010.1176/appi.ajp.163.1.2816390886 BrowningMKingslakeJDourishCTGoodwinGMHarmerCJDawsonGRPredicting treatment response to antidepressant medication using early changes in emotional processingEur Neuropsychopharmacol20192966751:CAS:528:DC%2BC1cXit1Crt77O10.1016/j.euroneuro.2018.11.110230473402 BoraEHarrisonBJYucelMPantelisCCognitive impairment in euthymic major depressive disorder: A meta-analysisPsychol Med2013432017261:STN:280:DC%2BC3s%2FotFemtA%3D%3D10.1017/S003329171200208523098294 MiskowiakKWCarvalhoAF‘Hot’ cognition in major depressive disorder: A systematic reviewCNS Neurological Disord - Drug Targets201413178780310.2174/1871527313666141130205713 EtkinAPatenaudeBSongYJUsherwoodTRekshanWSchatzbergAFA cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trialNeuropsychopharmacology.2015401332421:CAS:528:DC%2BC2MXhtFKktb8%3D10.1038/npp.2014.333255477114397406 McIntyreRSChaDSSoczynskaJKWoldeyohannesHOGallaugherLAKudlowPCognitive deficits and functional outcomes in major depressive disorder: Determinants, substrates, and treatment interventionsDepress Anxiety2013305152710.1002/da.2206323468126 SemkovskaMQuinlivanLO’GradyTJohnsonRCollinsAO’ConnorJCognitive function following a major depressive episode: A systematic review and meta-analysisLancet Psychiatry2019685161.10.1016/S2215-0366(19)30291-331422920 GrovesSJDouglasKMPorterRJA systematic review of cognitive predictors of treatment outcome in major depressionFront Psychiatry2018938210.3389/fpsyt.2018.00382302103686121150 GossAJKaserMCostafredaSGSahakianBJFuCHModafinil augmentation therapy in unipolar and bipolar depression: A systematic review and meta-analysis of randomized controlled trialsJ Clin Psychiatry201374110171:CAS:528:DC%2BC3sXhvF2kurzP10.4088/JCP.13r0856024330897 KaserMZamanRSahakianBJCognition as a treatment target in depressionPsychol Med20174798791:STN:280:DC%2BC1c%2FislajtQ%3D%3D10.1017/S003329171600312327938430 RoiserJPElliottRSahakianBJCognitive mechanisms of treatment in depressionNeuropsychopharmacology.201237117361:CAS:528:DC%2BC3MXhs1ejs77O10.1038/npp.2011.18321976044 HarmerCJCowenPJ‘It’s the way that you look at it’—a cognitive neuropsychological account of SSRI action in depressionPhilos Trans R Soc Lond Ser B, Biol Sci20133682012040710.1098/rstb.2012.0407 GodlewskaBRBrowningMNorburyRCowenPJHarmerCJEarly changes in emotional processing as a marker of clinical response to SSRI treatment in depressionTransl Psychiatry201661:CAS:528:DC%2BC28XhvFGgtr%2FE10.1038/tp.2016.130278748475314109 McIntyreRSLophavenSOlsenCKA randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adultsInt J Neuropsychopharmacol2014171557671:CAS:528:DC%2BC2cXhsFSitb3J10.1017/S146114571400054624787143 Godlewska BR, Harmer CJ. Cognitive neuropsychological theory of antidepressant action: A modern-day approach to depression and its treatment. Psychopharmacology. 2020;238:1265–78. Köhler-ForsbergKJorgensenADamVHStenbækDSFisherPMIpC-TPredicting treatment outcome in major depressive disorder using serotonin 4 receptor PET brain imaging, functional MRI, cognitive-, EEG-based, and peripheral biomarkers: A NeuroPharm open label clinical trial protocolFront Psychiatry20201164110.3389/fpsyt.2020.00641327929917391965 HolmSA simple sequentially rejective multiple test procedureScand J Stat197966570 S Holm (2240_CR25) 1979; 6 MH Trivedi (2240_CR2) 2006; 163 AJ Rush (2240_CR3) 2006; 163 C Shilyansky (2240_CR28) 2016; 3 M Semkovska (2240_CR18) 2019; 6 CJ Harmer (2240_CR16) 2013; 368 2240_CR24 RS McIntyre (2240_CR13) 2013; 30 SD Ostergaard (2240_CR21) 2016; 190 A Cleare (2240_CR26) 2015; 29 PL Rock (2240_CR7) 2014; 44 M Kaser (2240_CR12) 2017; 47 MJ Knight (2240_CR14) 2018; 31 2240_CR9 M Browning (2240_CR11) 2019; 29 C Park (2240_CR5) 2018; 353 2240_CR1 KW Miskowiak (2240_CR8) 2014; 13 2240_CR19 BW Dunlop (2240_CR22) 2019; 19 PY Collins (2240_CR4) 2011; 475 2240_CR15 2240_CR30 RS McIntyre (2240_CR27) 2014; 17 A Etkin (2240_CR10) 2015; 40 E Bora (2240_CR17) 2013; 43 SJ Groves (2240_CR6) 2018; 9 BR Godlewska (2240_CR31) 2016; 6 VH Dam (2240_CR23) 2019; 10 AJ Goss (2240_CR32) 2013; 74 K Köhler-Forsberg (2240_CR20) 2020; 11 JP Roiser (2240_CR29) 2012; 37 |
| References_xml | – reference: KnightMJBauneBTCognitive dysfunction in major depressive disorderCurr Opin Psychiatry201831263110.1097/YCO.000000000000037829076892 – reference: McIntyreRSLophavenSOlsenCKA randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adultsInt J Neuropsychopharmacol2014171557671:CAS:528:DC%2BC2cXhsFSitb3J10.1017/S146114571400054624787143 – reference: BoraEHarrisonBJYucelMPantelisCCognitive impairment in euthymic major depressive disorder: A meta-analysisPsychol Med2013432017261:STN:280:DC%2BC3s%2FotFemtA%3D%3D10.1017/S003329171200208523098294 – reference: GossAJKaserMCostafredaSGSahakianBJFuCHModafinil augmentation therapy in unipolar and bipolar depression: A systematic review and meta-analysis of randomized controlled trialsJ Clin Psychiatry201374110171:CAS:528:DC%2BC3sXhvF2kurzP10.4088/JCP.13r0856024330897 – reference: BrowningMKingslakeJDourishCTGoodwinGMHarmerCJDawsonGRPredicting treatment response to antidepressant medication using early changes in emotional processingEur Neuropsychopharmacol20192966751:CAS:528:DC%2BC1cXit1Crt77O10.1016/j.euroneuro.2018.11.110230473402 – reference: CleareAParianteCMYoungAHAndersonIMChristmasDCowenPJEvidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelinesJ Psychopharmacol2015294595251:CAS:528:DC%2BC2MXhtlWlu7%2FO10.1177/026988111558109325969470 – reference: EtkinAPatenaudeBSongYJUsherwoodTRekshanWSchatzbergAFA cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trialNeuropsychopharmacology.2015401332421:CAS:528:DC%2BC2MXhtFKktb8%3D10.1038/npp.2014.333255477114397406 – reference: Köhler-ForsbergKJorgensenADamVHStenbækDSFisherPMIpC-TPredicting treatment outcome in major depressive disorder using serotonin 4 receptor PET brain imaging, functional MRI, cognitive-, EEG-based, and peripheral biomarkers: A NeuroPharm open label clinical trial protocolFront Psychiatry20201164110.3389/fpsyt.2020.00641327929917391965 – reference: ShilyanskyCWilliamsLMGyurakAHarrisAUsherwoodTEtkinAEffect of antidepressant treatment on cognitive impairments associated with depression: A randomised longitudinal studyLancet Psychiatry201634253510.1016/S2215-0366(16)00012-2269952984860142 – reference: Ang YS, Bruder GE, Keilp JG, Rutherford A, Alschuler DM, Pechtel P, et al. Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychol Med. 2020:1–9. https://doi.org/10.1017/S0033291720004286. Epub ahead of print. – reference: RushAJTrivediMHWisniewskiSRNierenbergAAStewartJWWardenDAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D reportAm J Psychiatry200616319051710.1176/ajp.2006.163.11.190517074942 – reference: Hjordt LV, Ozenne B, Armand S, Dam VH, Jensen CG, Köhler-Forsberg K, et al. Psychometric properties of the verbal affective memory Test-26 and evaluation of affective biases in major depressive disorder. Front Psychol. 2020;11:961. – reference: HarmerCJCowenPJ‘It’s the way that you look at it’—a cognitive neuropsychological account of SSRI action in depressionPhilos Trans R Soc Lond Ser B, Biol Sci20133682012040710.1098/rstb.2012.0407 – reference: DunlopBWParikhSVRothschildAJThaseMEDeBattistaCConwayCRComparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBMC Psychiatry2019191:CAS:528:DC%2BC1MXisFSjs7vE10.1186/s12888-019-2410-2318819566935147 – reference: CollinsPYPatelVJoestlSSMarchDInselTRDaarASGrand challenges in global mental healthNature.201147527301:CAS:528:DC%2BC3MXosFehurs%3D10.1038/475027a217346853173804 – reference: KaserMZamanRSahakianBJCognition as a treatment target in depressionPsychol Med20174798791:STN:280:DC%2BC1c%2FislajtQ%3D%3D10.1017/S003329171600312327938430 – reference: OstergaardSDBechPMiskowiakKWFewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D(6)) as outcome measureJ Affect Disord2016190842510.1016/j.jad.2014.10.04725487682 – reference: HolmSA simple sequentially rejective multiple test procedureScand J Stat197966570 – reference: MiskowiakKWCarvalhoAF‘Hot’ cognition in major depressive disorder: A systematic reviewCNS Neurological Disord - Drug Targets201413178780310.2174/1871527313666141130205713 – reference: RoiserJPElliottRSahakianBJCognitive mechanisms of treatment in depressionNeuropsychopharmacology.201237117361:CAS:528:DC%2BC3MXhs1ejs77O10.1038/npp.2011.18321976044 – reference: GodlewskaBRBrowningMNorburyRCowenPJHarmerCJEarly changes in emotional processing as a marker of clinical response to SSRI treatment in depressionTransl Psychiatry201661:CAS:528:DC%2BC28XhvFGgtr%2FE10.1038/tp.2016.130278748475314109 – reference: GrovesSJDouglasKMPorterRJA systematic review of cognitive predictors of treatment outcome in major depressionFront Psychiatry2018938210.3389/fpsyt.2018.00382302103686121150 – reference: McIntyreRSChaDSSoczynskaJKWoldeyohannesHOGallaugherLAKudlowPCognitive deficits and functional outcomes in major depressive disorder: Determinants, substrates, and treatment interventionsDepress Anxiety2013305152710.1002/da.2206323468126 – reference: ParkCPanZBrietzkeESubramaniapillaiMRosenblatJDZuckermanHPredicting antidepressant response using early changes in cognition: A systematic reviewBehav Brain Res2018353154601:CAS:528:DC%2BC1cXhtl2jtbjM10.1016/j.bbr.2018.07.01130031025 – reference: RockPLRoiserJPRiedelWJBlackwellADCognitive impairment in depression: A systematic review and meta-analysisPsychol Med2014442029401:STN:280:DC%2BC2c7gslaquw%3D%3D10.1017/S003329171300253524168753 – reference: Pitsillou E, Bresnehan S, Kagarakis E, Wijoyo S, Liang J, Hung A, et al. The cellular and molecular basis of major depressive disorder: Towards a unified model for understanding clinical depression. Mol Biol Rep. 2019;47:753–70. – reference: TrivediMHRushAJWisniewskiSRNierenbergAAWardenDRitzLEvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry2006163284010.1176/appi.ajp.163.1.2816390886 – reference: Godlewska BR, Harmer CJ. Cognitive neuropsychological theory of antidepressant action: A modern-day approach to depression and its treatment. Psychopharmacology. 2020;238:1265–78. – reference: Dam VH, Stenbæk DS, Köhler-Forsberg K, Ip C, Ozenne B, Sahakian BJ, et al. Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: A NeuroPharm study. Psychol Med. 2020;51:1–10. – reference: DamVHThystrupCKJensenPSBlandARMortensenELElliottRPsychometric properties and validation of the EMOTICOM test battery in a healthy Danish populationFront Psychol201910266010.3389/fpsyg.2019.02660318497726901831 – reference: Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018;28:32–72. – reference: SemkovskaMQuinlivanLO’GradyTJohnsonRCollinsAO’ConnorJCognitive function following a major depressive episode: A systematic review and meta-analysisLancet Psychiatry2019685161.10.1016/S2215-0366(19)30291-331422920 – volume: 29 start-page: 459 year: 2015 ident: 2240_CR26 publication-title: J Psychopharmacol doi: 10.1177/0269881115581093 – volume: 10 start-page: 2660 year: 2019 ident: 2240_CR23 publication-title: Front Psychol doi: 10.3389/fpsyg.2019.02660 – volume: 13 start-page: 1787 year: 2014 ident: 2240_CR8 publication-title: CNS Neurological Disord - Drug Targets doi: 10.2174/1871527313666141130205713 – volume: 47 start-page: 987 year: 2017 ident: 2240_CR12 publication-title: Psychol Med doi: 10.1017/S0033291716003123 – ident: 2240_CR19 doi: 10.1017/S0033291720000938 – volume: 475 start-page: 27 year: 2011 ident: 2240_CR4 publication-title: Nature. doi: 10.1038/475027a – volume: 31 start-page: 26 year: 2018 ident: 2240_CR14 publication-title: Curr Opin Psychiatry doi: 10.1097/YCO.0000000000000378 – volume: 43 start-page: 2017 year: 2013 ident: 2240_CR17 publication-title: Psychol Med doi: 10.1017/S0033291712002085 – volume: 11 start-page: 641 year: 2020 ident: 2240_CR20 publication-title: Front Psychiatry doi: 10.3389/fpsyt.2020.00641 – ident: 2240_CR15 doi: 10.1007/s11065-018-9369-5 – volume: 19 year: 2019 ident: 2240_CR22 publication-title: BMC Psychiatry doi: 10.1186/s12888-019-2410-2 – volume: 6 year: 2016 ident: 2240_CR31 publication-title: Transl Psychiatry doi: 10.1038/tp.2016.130 – volume: 353 start-page: 154 year: 2018 ident: 2240_CR5 publication-title: Behav Brain Res doi: 10.1016/j.bbr.2018.07.011 – volume: 6 start-page: 65 year: 1979 ident: 2240_CR25 publication-title: Scand J Stat – volume: 37 start-page: 117 year: 2012 ident: 2240_CR29 publication-title: Neuropsychopharmacology. doi: 10.1038/npp.2011.183 – volume: 40 start-page: 1332 year: 2015 ident: 2240_CR10 publication-title: Neuropsychopharmacology. doi: 10.1038/npp.2014.333 – volume: 3 start-page: 425 year: 2016 ident: 2240_CR28 publication-title: Lancet Psychiatry doi: 10.1016/S2215-0366(16)00012-2 – volume: 44 start-page: 2029 year: 2014 ident: 2240_CR7 publication-title: Psychol Med doi: 10.1017/S0033291713002535 – volume: 17 start-page: 1557 year: 2014 ident: 2240_CR27 publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145714000546 – ident: 2240_CR30 doi: 10.1017/S0033291720004286 – volume: 74 start-page: 1101 year: 2013 ident: 2240_CR32 publication-title: J Clin Psychiatry doi: 10.4088/JCP.13r08560 – ident: 2240_CR1 doi: 10.1007/s11033-019-05129-3 – volume: 30 start-page: 515 year: 2013 ident: 2240_CR13 publication-title: Depress Anxiety doi: 10.1002/da.22063 – volume: 368 start-page: 20120407 year: 2013 ident: 2240_CR16 publication-title: Philos Trans R Soc Lond Ser B, Biol Sci doi: 10.1098/rstb.2012.0407 – ident: 2240_CR9 doi: 10.1007/s00213-019-05448-0 – volume: 163 start-page: 1905 year: 2006 ident: 2240_CR3 publication-title: Am J Psychiatry doi: 10.1176/ajp.2006.163.11.1905 – volume: 6 start-page: 851 year: 2019 ident: 2240_CR18 publication-title: Lancet Psychiatry doi: 10.1016/S2215-0366(19)30291-3 – volume: 163 start-page: 28 year: 2006 ident: 2240_CR2 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.163.1.28 – ident: 2240_CR24 doi: 10.3389/fpsyg.2020.00961 – volume: 9 start-page: 382 year: 2018 ident: 2240_CR6 publication-title: Front Psychiatry doi: 10.3389/fpsyt.2018.00382 – volume: 29 start-page: 66 year: 2019 ident: 2240_CR11 publication-title: Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2018.11.1102 – volume: 190 start-page: 842 year: 2016 ident: 2240_CR21 publication-title: J Affect Disord doi: 10.1016/j.jad.2014.10.047 |
| SSID | ssj0000548171 |
| Score | 2.3963509 |
| Snippet | Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of antidepressant... Abstract Cognitive disturbances in major depressive disorder (MDD) constitute a critical treatment target and hold promise as an early predictor of... |
| SourceID | doaj pubmedcentral proquest crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 468 |
| SubjectTerms | 692/53/2423 692/699/476/1414 Antidepressants Behavioral Sciences Biological Psychology Medicine Medicine & Public Health Mental depression Neurosciences Pharmacotherapy Psychiatry |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5VFaq4IKAgAqUyUm8Q1Y6dxOZWUCsuVD0UqTfLcWxYBNlqs8tb8M6MfzZtKhUu3CLbcWzPjGccz3wDcMRbI3vueGnqLqQw61nZWe7KphZO8k60kpuYbKI9P5dXV-riVqqv4BOW4IHTwh03HSo4G_S6EyJggSvjUctZbmnruYuhe2j13DpMJVRvIVnLcpQM5fJ4xN06RJPh2SuqsZLNNFEE7J9ZmXd9JO9clEb9c_YYHmXDkZykAT-BHTc8hb3P-Wp8H36fZtzu4SuZfIJIj1TcrLpA2pGYkUx-5SS5gBMz9OR6FXrBwzdZeixYL7J7LD6SFPdAFgP5ab5ji63nbOo7Ane-JyckYnxcBBhsEgFrn8GXs9PLj5_KnGuhtDVr12UlXG16FryovWJOqKqjCm0HTztDeaV64Wlj0RpwvWcOHxl1yttGVbbh1lL-HHaH5eBeADG9k9YxYUWtBEUSUUuFo9yjcdH6jhfAtuuubQYiD_kwfuh4Ic6lTrTSSCcdaaVZAW-nd64TDMdfW38I5JxaBgjtWICMpTNj6X8xVgEHW2bQWa5HjcYel42slSzgzVSNEhmuWczglpvYRjQMDUnsop0x0WxA85ph8S1iewd4NNzzC3i3Zbebj98_4Zf_Y8Kv4GEVxCP-Mz-A3fVq417DA_trvRhXh1G-_gANjinT priority: 102 providerName: Directory of Open Access Journals |
| Title | Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study |
| URI | https://link.springer.com/article/10.1038/s41398-022-02240-1 https://www.proquest.com/docview/2733868598 https://www.proquest.com/docview/2734616009 https://pubmed.ncbi.nlm.nih.gov/PMC9643376 https://doaj.org/article/6b175c5514e4435589af750c3c07f3e9 |
| Volume | 12 |
| WOSCitedRecordID | wos000880336000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2158-3188 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000548171 issn: 2158-3188 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2158-3188 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000548171 issn: 2158-3188 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2158-3188 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0000548171 issn: 2158-3188 databaseCode: 7X7 dateStart: 20220101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2158-3188 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0000548171 issn: 2158-3188 databaseCode: BENPR dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2158-3188 dateEnd: 20221231 omitProxy: false ssIdentifier: ssj0000548171 issn: 2158-3188 databaseCode: PIMPY dateStart: 20220101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELXoFiEufKMGyspI3CCqHTuJzQW1aCs47CpCIC2nyHGcsogmS7LLkX_Af2bsOKlSiV64RJHjOI489jzPjN8g9IqlSpTMsFDFhU1hVtKw0MyEScyNYAVPBVMu2US6Won1Wmbe4Nb5sMphTXQLddloayM_ATXLRCJiKd5tf4Y2a5T1rvoUGgfo0DKV8Rk6PFussk-jlQUAiaAp9adlCBMnHaza9lQZ7MGcOgvpRCM54v4J2rweK3nNYer00Pn9__2DB-ieR6D4tBeZh-iWqR-hO0vvY3-M_iw8AXh9gcfgIlyCOOzbwspIh1WHxwB13MeSY1WXeNvaVmAXj5sKCnYbH2cLt7g_QIE3Nb5U36HGEILbt-0YQN_iU-zIQjLLp40d8-0T9OV88fn9h9AnbQh1TNNdGHETq5LacOxKUsNlVBAJIKQihSIskiWvSKIBVpiyogZuKTGy0omMdMK0JuwpmtVNbY4QVqUR2lCueSw5YUYSTbghrAKUklYFCxAdBi7XntHcJtb4kTvPOhN5P9g5DHTuBjunAXo9vrPt-TxurH1m5WGsabm4XUHTXuR-audJARBMW-RpOLds9VJVgMM00yStoNcBOh7kIfcLRJdfCUOAXo6PYWpbf42qTbN3dXhCAZFCE-lECicdmj6pN98cSbjlWQPlEaA3g7xeffzfP_zs5r4-R3cjO3OcWf0YzXbt3rxAt_Wv3aZr5-ggXafuKuZ-Is6djQOuy98LKMs-LrOvfwGLAUAJ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFLXKFAEb3oiBAkaCFUS1YyexkRAq0KqjdkazKFJZGcdxyiBIhiQD4iP4Fb6Ra-dRTSW664JdlDiOk5z7SHx8LkLPWKJFxiwLdJS6EmYZDVLDbBBH3AqW8kQw7YtNJLOZOD6W8w30p18L42iVvU_0jjorjftHvg1hlolYRFK8WX4PXNUoN7val9BoYXFgf_2ET7b69eQ9vN_nYbi3e_RuP-iqCgQmokkThNxGOqOOL5xLarkMUyIhSuYk1YSFMuM5iQ3EPZvl1MImJVbmJpahiZkxhEG_l9AmB7CLEdqcT6bzj8NfHUiABE1otzqHMLFdQ5Rwq9jgm8-Hz4CuRUBfKGAtuz3LzTwzQevj3t6N_-2J3UTXuwwb77QmcQtt2OI2ujLtOAR30O_dTuC8OMEDeQpnAPdVlTobqLGu8UDAxy1XHusiw8vK9dKUFS5z2NEsOh4xbOJ2gQheFPib_gIteopx27dXOH2Fd7AXQ5k7vXDslX3vog8X8jDuoVFRFvY-wjqzwljKDY8kJ8xKYgi3hOWQhSV5ysaI9kBRplNsd4VDvirPHGBCteBSACzlwaXoGL0Yzlm2eiXntn7r8De0dFrjfkdZnajOdak4hRTTuMzacu7U-KXOIc80zJAkh1GP0VaPP9U5wFqdgm-Mng6HwXW5-Shd2HLl2_CYQsYNXSRrqF8b0PqRYvHZi6A7HTkIjmP0sreP04v_-4YfnD_WJ-jq_tH0UB1OZgcP0bXQWa2fQthCo6Za2UfosvnRLOrqcWf4GH26aMv5C9nml3Y |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFLVKiyo2vBEDBYwEK4jGjp3ERkKo0FaMSkezAKmsjOPYZRAkQzID4iP4Ib6Oa-dRTSW664JdlDiOk9zHSXx8LkJPWKZFwSyLdJL7EmYFjXLDbJQm3AqW80wwHYpNZNOpOD6Wsw30p18L42mVfUwMgbqojP9HPoY0y0QqEinGrqNFzPYOXi2-R76ClJ9p7ctptCZyaH_9hM-35uVkD9710zg-2H__5m3UVRiITEKzZRRzm-iCeu6wk9RyGedEQsZ0JNeExbLgjqQGcqAtHLWwSYmVzqQyNikzhjDo9xLaAkjOwce2ZpOj2cfhDw-AIUEz2q3UIUyMG8gYfkUbfP-FVBrRtWwYigasId2zPM0zk7UhBx5c-5-f3nV0tUPeeLd1lRtow5Y30fZRxy24hX7vd8Ln5QkeSFW4ADdY1bn3jQbrBg_EfNxy6LEuC7yofS_LqsaVgx3Leccvhk3cLhzB8xJ_01-gRU89bvsOyqcv8C4OIikzryOOg-LvbfThQh7GHbRZVqW9i7AurDCWcsMTyQmzkhjCLWEO0FnmcjZCtDcaZTold19Q5KsKjAImVGtoCoxMBUNTdISeDecsWh2Tc1u_9rY4tPQa5GFHVZ-oLqSpNAfoaTzitpx7lX6pHeBPwwzJHIx6hHZ6W1RdYGzUqSGO0OPhMIQ0P0-lS1utQhueUkDi0EW25gFrA1o_Us4_B3F0ry8HSXOEnve-cnrxf9_wvfPH-ghtg7uod5Pp4X10JfYOHGYWdtDmsl7ZB-iy-bGcN_XDLgZg9OmiHecvutigNg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+cognitive+disturbances+as+treatment+target+and+predictor+of+antidepressant+action+in+major+depressive+disorder%3A+A+NeuroPharm+study&rft.jtitle=Translational+psychiatry&rft.au=Dam%2C+Vibeke+H%C3%B8yrup&rft.au=Stenb%C3%A6k%2C+Dea+Siggaard&rft.au=K%C3%B6hler-Forsberg%2C+Kristin&rft.au=Ozenne%2C+Brice&rft.date=2022-11-08&rft.issn=2158-3188&rft.eissn=2158-3188&rft.volume=12&rft.issue=1&rft.spage=468&rft_id=info:doi/10.1038%2Fs41398-022-02240-1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2158-3188&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2158-3188&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2158-3188&client=summon |